Last edition
News about "Positive interim Phase 2 results for SSGJ-707 as a"
The next phase of clinical development will span the U.S. and global trial sites, with a priority focus on launching Phase 3 trials for NSCLC and other solid tumors, beginning with patient enrollment in the U.S.
Positive Interim Phase 2 Results For SSGJ-707 As A | 25/07/2025 | By Darshana | 425
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members